Dihydroartemisinin induces apoptosis of cervical cancer cells via upregulation of RKIP and downregulation of bcl-2

Cancer Biology and Therapy

Volumn 15, Issue 3, 2014, Pages 279-288

  Hu, Chun Jie ^a   Zhou, Lei ^b   Cai, Yan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Bcl 2; Cervival cancer; Dihydroartemisinin; Metastasis; Raf kinase inhibitor protein; Tumor

Indexed keywords

DIHYDROARTEMISININ; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN BCL 2; ANTINEOPLASTIC AGENT; ARTEMISININ DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DEVELOPING COUNTRY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; UTERINE CERVIX CANCER; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME; UTERINE CERVIX TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARTEMISININS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR BURDEN; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 84896511753     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.27223     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.org/ 10.3322/caac.20107
2. Peralta-Zaragoza O, Deas J, Gómez-Cerón C, García-Suastegui WA, Fierros-Zárate Gdel S, Jacobo-Herrera NJ. HPV-Based Screening, Triage, Treatment, and Followup Strategies in the Management of Cervical Intraepithelial Neoplasia. Obstet Gynecol Int 2013; 2013:912780; PMID:23690785; http://dx.doi.org/10.1155/2013/912780
3. Luhn P, Wentzensen N. HPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease. Curr Obstet Gynecol Rep 2013; 2:76-85; PMID:23705102; http://dx.doi.org/10.1007/s13669-013-0040-0
4. Mathew A, George PS. Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix-worldwide. Asian Pac J Cancer Prev 2009; 10:645-50; PMID:19827887
5. Iida K, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Yeasmin S, Otsuki Y, Kobayashi H, Nakayama S, et al. EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target. Br J Cancer 2011; 105:420-7; PMID:21730982; http://dx.doi.org/10.1038/bjc.2011.222
6. Kawana K, Adachi K, Kojima S, Kozuma S, Fujii T. Therapeutic Human Papillomavirus (HPV) Vaccines: A Novel Approach. Open Virol J 2012; 6:264-9; PMID:23341862; http://dx.doi.org/10.2174/1874357901206010264
7. Denny L. Cervical cancer: prevention and treatment. Discov Med 2012; 14:125-31; PMID:22935209
8. Lee S. Artemisinin, promising lead natural product for various drug developments. Mini Rev Med Chem 2007; 7:411-22; PMID:17430226; http://dx.doi.org/10.2174/138955707780363837 (Pubitemid 46681763)
9. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol 2001; 18:767-73; PMID:11251172
10. Hien TT, White NJ. Qinghaosu. Lancet 1993; 341:603-8; PMID:8094838; http://dx.doi.org/10.1016/0140-6736(93)90362-K (Pubitemid 23066156)
11. Chen HH, Zhou HJ, Fang X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res 2003; 48:231-6; PMID:12860439; http://dx.doi.org/10. 1016/S1043-6618(03)00107-5 (Pubitemid 36818928)
12. Disbrow GL, Baege AC, Kierpiec KA, Yuan H, Centeno JA, Thibodeaux CA, Hartmann D, Schlegel R. Dihydroartemisinin is cytotoxic to papillomavirus- expressing epithelial cells in vitro and in vivo. Cancer Res 2005; 65:10854-61; PMID:16322232; http://dx.doi.org/10.1158/0008-5472.CAN-05-1216 (Pubitemid 41713353)
13. Chen H, Sun B, Pan S, Jiang H, Sun X. Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer Drugs 2009; 20:131-40; PMID:19209030; http://dx.doi.org/10.1097/CAD.0b013e3283212ade
14. Wu GS, Lu JJ, Guo JJ, Huang MQ, Gan L, Chen XP, Wang YT. Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells. Pharmacol Rep 2013; 65:453-9; PMID:23744430
15. Du XX, Li YJ, Wu CL, Zhou JH, Han Y, Sui H, Wei XL, Liu L, Huang P, Yuan HH, et al. Initiation of apoptosis, cell cycle arrest and autophagy of esophageal cancer cells by dihydroartemisinin. Biomed Pharmacother 2013; 67:417-24; PMID:23582790; http://dx.doi.org/10.1016/j.biopha.2013.01.013
16. Luo J, Chen X, Chen G, Zhou X, Lu X, Ling Y, Zhang S, Zhu W, Cao J. Dihydroartemisinin induces radiosensitivity in cervical cancer cells by modulating cell cycle progression. Saudi Med J 2013; 34:254-60; PMID:23475089
17. Wang SJ, Gao Y, Chen H, Kong R, Jiang HC, Pan SH, Xue DB, Bai XW, Sun B. Dihydroartemisinin inactivates NF-kappaB and potentiates the antitumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett 2010; 293:99-108; PMID:20137856; http://dx.doi.org/10.1016/j. canlet.2010.01.001
18. Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B, García JJ, Kolch W. Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res 2005; 11:7392-7; PMID:16243812; http://dx.doi.org/10.1158/1078-0432.CCR-05-0283 (Pubitemid 41507699)
19. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, Keller ET. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 2003; 95:878-89; PMID:12813171; http://dx.doi.org/10.1093/jnci/95.12.878 (Pubitemid 36833879)
20. Li HZ, Wang Y, Gao Y, Shao J, Zhao XL, Deng WM, Liu YX, Yang J, Yao Z. Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer. Mol Cancer Res 2008; 6:917-28; PMID:18567796; http://dx.doi.org/10.1158/1541-7786.MCR-08-0093
21. Al-Awadhi R, Husain S, Chehadeh W, Al-Jassar W, Kapila K, Al-Mulla F. Immunocytochemical detection of raf kinase inhibitor protein and human papillomavirus profiling of normal and abnormal cervical Thin Prep samples. Acta Cytol 2013; 57:259-65; PMID:23636063; http://dx.doi.org/10.1159/000350249
22. Al-Mulla F, Bitar MS, Taqi Z, Yeung KC. RKIP: much more than Raf kinase inhibitory protein. J Cell Physiol 2013; 228:1688-702; PMID:23359513; http://dx.doi.org/10.1002/jcp.24335
23. Hu CJ, Zhou L, Zhang J, Huang C, Zhang GM. Immunohistochemical detection of Raf kinase inhibitor protein in normal cervical tissue and cervical cancer tissue. J Int Med Res 2011; 39:229-37; PMID:21672326; http://dx.doi.org/10.1177/ 147323001103900125
24. Martinho O, Pinto F, Granja S, Miranda-Gonçalves V, Moreira MA, Ribeiro LF, di Loreto C, Rosner MR, Longatto-Filho A, Reis RM. RKIP inhibition in cervical cancer is associated with higher tumor aggressive behavior and resistance to cisplatin therapy. PLoS One 2013; 8:e59104; PMID:23527098; http://dx.doi.org/10.1371/journal.pone.0059104
25. Peralta-Zaragoza O, Bermúdez-Morales VH, Pérez-Plasencia C, Salazar-León J, Gómez-Cerón C, Madrid-Marina V. Targeted treatments for cervical cancer: a review. Onco Targets Ther 2012; 5:315-28; PMID:23144564; http://dx.doi.org/10.2147/OTT. S25123
26. Efferth T, Benakis A, Romero MR, Tomicic M, Rauh R, Steinbach D, Häfer R, Stamminger T, Oesch F, Kaina B, et al. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med 2004; 37:998-1009; PMID:15336316; http://dx.doi.org/10.1016/j. freeradbiomed.2004.06. 023 (Pubitemid 39164582)
27. Lu JJ, Meng LH, Cai YJ, Chen Q, Tong LJ, Lin LP, Ding J. Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. Cancer Biol Ther 2008; 7:1017-23; PMID:18414062; http://dx.doi.org/10.4161/cbt.7.7.6035
28. Ferreira JF, Luthria DL, Sasaki T, Heyerick A. Flavonoids from Artemisia annua L. as antioxidants and their potential synergism with artemisinin against malaria and cancer. Molecules 2010; 15:3135-70; PMID:20657468; http://dx.doi.org/10.3390/molecules15053135
29. Zhang XM, Gu H, Yan L, Zhang GY. RKIP inhibits the malignant phenotypes of gastric cancer cells. Neoplasma 2012; (Forthcoming) PMID:23176280; http://dx.doi.org/10.4149/neo-2013-026
30. al-Mulla F, Bitar MS, Taqi Z, Rath O, Kolch W. RAF kinase inhibitory protein (RKIP) modulates cell cycle kinetics and motility. Mol Biosyst 2011; 7:928-41; PMID:21180766; http://dx.doi.org/10.1039/c0mb00208a
31. Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene 2009; 28:3573-85; PMID:19633685; http://dx.doi.org/10.1038/onc.2009.214
32. Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W, Sedivy JM. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol 2001; 21:7207-17; PMID:11585904; http://dx.doi.org/10.1128/MCB.21.21. 7207-7217.2001 (Pubitemid 32953475)
33. Wu K, Bonavida B. The activated NF-kappaB Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit Rev Immunol 2009; 29:241-54; PMID:19538137; http://dx.doi.org/10. 1615/CritRevImmunol.v29.i3.40
34. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9:351-65; PMID:16697956; http://dx.doi.org/10.1016/j.ccr.2006.03.027 (Pubitemid 43668734)
35. Liu Z, Lu H, Jiang Z, Pastuszyn A, Hu CA. Apolipoprotein 16, a novel proapoptotic Bcl-2 homology 3-only protein, induces mitochondria-mediated apoptosis in cancer cells. Mol Cancer Res 2005; 3:21-31; PMID:15671246 (Pubitemid 40189593)
36. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435:677-81; PMID:15902208; http://dx.doi.org/10.1038/nature03579 (Pubitemid 40825512)
37. Van Brocklin MW, Verhaegen M, Soengas MS, Holmen SL. Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. Cancer Res 2009; 69:1985-94; PMID:19244105; http://dx.doi.org/10.1158/ 0008-5472.CAN-08-3934
38. Schwarz CS, Evert BO, Seyfried J, Schaupp M, Kunz WS, Vielhaber S, Klockgether T, Wüllner U. Overexpression of bcl-2 results in reduction of cytochrome c content and inhibition of complex I activity. Biochem Biophys Res Commun 2001; 280:1021-7; PMID:11162629; http://dx.doi.org/10.1006/bbrc.2001.4242 (Pubitemid 32924442)
39. Al-Mulla F, Bitar MS, Al-Maghrebi M, Behbehani AI, Al-Ali W, Rath O, Doyle B, Tan KY, Pitt A, Kolch W. Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3β. Cancer Res 2011; 71:1334-43; PMID:21303975; http://dx.doi.org/10.1158/0008-5472.CAN-10-3102